Minimális reziduális betegség monitorozása gyermekkori akut leukémiában a WT1 gén perifé riás vérben történo expressziójának nyomonkövetésével

Translated title of the contribution: Nested PCR detection of WT1 expression in the peripheral blood in childhood acute leukemia

E. Rásó, Norbert Varga, J. Tímár, Edina Magyarosy

Research output: Contribution to journalArticle

Abstract

Detection of minimal residual disease (MRD) in childhood leukemia is not possible by cytomorphology or Southern blotting due to their low sensitivity. On the other hand, the use of DNA markers and PCR amplification is helpful in a smaller proportion of leukemia cases (20-30%). Since childhood leukemia is characterized by WT1 gene expression in the majority of cases, monitoring of WT1 expression in the peripheral blood was suggested to be a method of choice to detect MRD. We have studied 22 newly diagnosed childhood acute leukemias and 17 cases in remission. As controls, 19 patients with non-leukemic diseases were included. The majority of our acute leukemia cases (80%) were proved to be WT1 expressors using a highly sensitive nested PCR technique. Ten WT1+ cases have been monitored for a year throughout the inicial therapy phase, using peripheral blood tests. We observed that in 20% of the follow-up cases MRD was suggested which was not detectable by any other methods. It is our intention to introduce this new molecular technique into the clinical management of childhood acute leukemia.

Original languageHungarian
Pages (from-to)297-303
Number of pages7
JournalMagyar Onkologia
Volume44
Issue number4
Publication statusPublished - 2000

Fingerprint

Leukemia
Polymerase Chain Reaction
Residual Neoplasm
Hematologic Tests
Southern Blotting
Genetic Markers
Gene Expression
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

@article{8b2dd40f00764a65a600999a9cc9a98f,
title = "Minim{\'a}lis rezidu{\'a}lis betegs{\'e}g monitoroz{\'a}sa gyermekkori akut leuk{\'e}mi{\'a}ban a WT1 g{\'e}n perif{\'e} ri{\'a}s v{\'e}rben t{\"o}rt{\'e}no expresszi{\'o}j{\'a}nak nyomonk{\"o}vet{\'e}s{\'e}vel",
abstract = "Detection of minimal residual disease (MRD) in childhood leukemia is not possible by cytomorphology or Southern blotting due to their low sensitivity. On the other hand, the use of DNA markers and PCR amplification is helpful in a smaller proportion of leukemia cases (20-30{\%}). Since childhood leukemia is characterized by WT1 gene expression in the majority of cases, monitoring of WT1 expression in the peripheral blood was suggested to be a method of choice to detect MRD. We have studied 22 newly diagnosed childhood acute leukemias and 17 cases in remission. As controls, 19 patients with non-leukemic diseases were included. The majority of our acute leukemia cases (80{\%}) were proved to be WT1 expressors using a highly sensitive nested PCR technique. Ten WT1+ cases have been monitored for a year throughout the inicial therapy phase, using peripheral blood tests. We observed that in 20{\%} of the follow-up cases MRD was suggested which was not detectable by any other methods. It is our intention to introduce this new molecular technique into the clinical management of childhood acute leukemia.",
author = "E. R{\'a}s{\'o} and Norbert Varga and J. T{\'i}m{\'a}r and Edina Magyarosy",
year = "2000",
language = "Hungarian",
volume = "44",
pages = "297--303",
journal = "Magyar Onkologia",
issn = "0025-0244",
publisher = "Akademiai Kiado",
number = "4",

}

TY - JOUR

T1 - Minimális reziduális betegség monitorozása gyermekkori akut leukémiában a WT1 gén perifé riás vérben történo expressziójának nyomonkövetésével

AU - Rásó, E.

AU - Varga, Norbert

AU - Tímár, J.

AU - Magyarosy, Edina

PY - 2000

Y1 - 2000

N2 - Detection of minimal residual disease (MRD) in childhood leukemia is not possible by cytomorphology or Southern blotting due to their low sensitivity. On the other hand, the use of DNA markers and PCR amplification is helpful in a smaller proportion of leukemia cases (20-30%). Since childhood leukemia is characterized by WT1 gene expression in the majority of cases, monitoring of WT1 expression in the peripheral blood was suggested to be a method of choice to detect MRD. We have studied 22 newly diagnosed childhood acute leukemias and 17 cases in remission. As controls, 19 patients with non-leukemic diseases were included. The majority of our acute leukemia cases (80%) were proved to be WT1 expressors using a highly sensitive nested PCR technique. Ten WT1+ cases have been monitored for a year throughout the inicial therapy phase, using peripheral blood tests. We observed that in 20% of the follow-up cases MRD was suggested which was not detectable by any other methods. It is our intention to introduce this new molecular technique into the clinical management of childhood acute leukemia.

AB - Detection of minimal residual disease (MRD) in childhood leukemia is not possible by cytomorphology or Southern blotting due to their low sensitivity. On the other hand, the use of DNA markers and PCR amplification is helpful in a smaller proportion of leukemia cases (20-30%). Since childhood leukemia is characterized by WT1 gene expression in the majority of cases, monitoring of WT1 expression in the peripheral blood was suggested to be a method of choice to detect MRD. We have studied 22 newly diagnosed childhood acute leukemias and 17 cases in remission. As controls, 19 patients with non-leukemic diseases were included. The majority of our acute leukemia cases (80%) were proved to be WT1 expressors using a highly sensitive nested PCR technique. Ten WT1+ cases have been monitored for a year throughout the inicial therapy phase, using peripheral blood tests. We observed that in 20% of the follow-up cases MRD was suggested which was not detectable by any other methods. It is our intention to introduce this new molecular technique into the clinical management of childhood acute leukemia.

UR - http://www.scopus.com/inward/record.url?scp=84875195577&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875195577&partnerID=8YFLogxK

M3 - Article

VL - 44

SP - 297

EP - 303

JO - Magyar Onkologia

JF - Magyar Onkologia

SN - 0025-0244

IS - 4

ER -